Ronina A Covar1, Stanley J Szefler2, Robert S Zeiger3, Christine A Sorkness4, Mark Moss4, David T Mauger5, Susan J Boehmer5, Robert C Strunk6, Fernando D Martinez7, Lynn M Taussig2. 1. Department of Pediatrics, National Jewish Medical and Research Center and University of Colorado Health Sciences Center, Denver, Colo. Electronic address: covarr@njc.org. 2. Department of Pediatrics, National Jewish Medical and Research Center and University of Colorado Health Sciences Center, Denver, Colo. 3. Department of Pediatrics, University of California San Diego, and the Department of Allergy, Kaiser Permanente, San Diego, Calif. 4. Clinical Science Center, University of Wisconsin, and the Department of Pediatrics, University of California-San Diego, San Diego, Calif. 5. Department of Public Health Sciences, Pennsylvania State University, Hershey, Pa. 6. Department of Pediatrics, Washington University, St Louis, Mo. 7. Arizona Respiratory Center, University of Arizona, Tucson, Ariz.
Abstract
BACKGROUND: Asthma exacerbations are a common cause of critical illness in children. OBJECTIVE: To determine factors associated with exacerbations in children with persistent asthma. METHODS: Regression modeling was used to identify historical, phenotypic, treatment, and time-dependent factors associated with the occurrence of exacerbations, defined by need for oral corticosteroids or emergency or hospital care in the 48-week Pediatric Asthma Controller Trial study. Children age 6 to 14 years with mild-to-moderate persistent asthma were randomized to receive either fluticasone propionate 100 microg twice daily (FP monotherapy), combination fluticasone 100 microg AM and salmeterol twice daily, or montelukast 5 mg once daily. RESULTS: Of the 285 participants randomized, 48% had 231 exacerbations. Using a multivariate analysis, which included numerous demographic, pulmonary, and inflammatory parameters, only a history of an asthma exacerbation requiring a systemic corticosteroid in the past year (odds ratio [OR], 2.10; P < .001) was associated with a subsequent exacerbation during the trial. During the trial, treatment with montelukast versus FP monotherapy (OR, 2.00; P = .005), season (spring, fall, or winter vs summer; P < or = .001), and average seasonal 5% reduction in AM peak expiratory flow (OR, 1.21; P = .01) were each associated with exacerbations. Changes in worsening of symptoms, beta-agonist use, and low peak expiratory flow track together before an exacerbation, but have poor positive predictive value of exacerbation. CONCLUSION:Children with mild-to-moderate persistent asthma with previous exacerbations are more likely to have a repeat exacerbation despite controller treatment. Inhaled corticosteroids are superior to montelukast at modifying the exacerbation risk. Available physiologic measures and biomarkers and diary card tracking are not reliable predictors of asthma exacerbations.
RCT Entities:
BACKGROUND:Asthma exacerbations are a common cause of critical illness in children. OBJECTIVE: To determine factors associated with exacerbations in children with persistent asthma. METHODS: Regression modeling was used to identify historical, phenotypic, treatment, and time-dependent factors associated with the occurrence of exacerbations, defined by need for oral corticosteroids or emergency or hospital care in the 48-week Pediatric Asthma Controller Trial study. Children age 6 to 14 years with mild-to-moderate persistent asthma were randomized to receive either fluticasone propionate 100 microg twice daily (FP monotherapy), combination fluticasone 100 microg AM and salmeterol twice daily, or montelukast 5 mg once daily. RESULTS: Of the 285 participants randomized, 48% had 231 exacerbations. Using a multivariate analysis, which included numerous demographic, pulmonary, and inflammatory parameters, only a history of an asthma exacerbation requiring a systemic corticosteroid in the past year (odds ratio [OR], 2.10; P < .001) was associated with a subsequent exacerbation during the trial. During the trial, treatment with montelukast versus FP monotherapy (OR, 2.00; P = .005), season (spring, fall, or winter vs summer; P < or = .001), and average seasonal 5% reduction in AM peak expiratory flow (OR, 1.21; P = .01) were each associated with exacerbations. Changes in worsening of symptoms, beta-agonist use, and low peak expiratory flow track together before an exacerbation, but have poor positive predictive value of exacerbation. CONCLUSION:Children with mild-to-moderate persistent asthma with previous exacerbations are more likely to have a repeat exacerbation despite controller treatment. Inhaled corticosteroids are superior to montelukast at modifying the exacerbation risk. Available physiologic measures and biomarkers and diary card tracking are not reliable predictors of asthma exacerbations.
Authors: Stanley Szefler; Scott Weiss; James Tonascia; N Franklin Adkinson; Bruce Bender; Reuben Cherniack; Michele Donithan; H William Kelly; Joseph Reisman; Gail G Shapiro; Alice L Sternberg; Robert Strunk; Virginia Taggart; Mark Van Natta; Robert Wise; Margaret Wu; Robert Zeiger Journal: N Engl J Med Date: 2000-10-12 Impact factor: 91.245
Authors: Finn Rasmussen; D Robin Taylor; Erin M Flannery; Jan O Cowan; Justina M Greene; G Peter Herbison; Malcolm R Sears Journal: J Allergy Clin Immunol Date: 2002-08 Impact factor: 10.793
Authors: Romain A Pauwels; Søren Pedersen; William W Busse; Wan C Tan; Yu-Zhi Chen; Stefan V Ohlsson; Anders Ullman; Carl Johan Lamm; Paul M O'Byrne Journal: Lancet Date: 2003-03-29 Impact factor: 79.321
Authors: Mathew J Reeves; Sarah Lyon-Callo; Michael D Brown; Ken Rosenman; Elizabeth Wasilevich; Seymour G Williams Journal: Pediatrics Date: 2006-04 Impact factor: 7.124
Authors: Christine A Sorkness; Robert F Lemanske; David T Mauger; Susan J Boehmer; Vernon M Chinchilli; Fernando D Martinez; Robert C Strunk; Stanley J Szefler; Robert S Zeiger; Leonard B Bacharier; Gordon R Bloomberg; Ronina A Covar; Theresa W Guilbert; Gregory Heldt; Gary Larsen; Michael H Mellon; Wayne J Morgan; Mark H Moss; Joseph D Spahn; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2006-11-30 Impact factor: 10.793
Authors: Karen McCoy; David M Shade; Charles G Irvin; John G Mastronarde; Nicola A Hanania; Mario Castro; N R Anthonisen Journal: J Allergy Clin Immunol Date: 2006-10-23 Impact factor: 10.793
Authors: Loren C Denlinger; Ron L Sorkness; Wai-Ming Lee; Michael D Evans; Michele J Wolff; Sameer K Mathur; Gina M Crisafi; Katie L Gaworski; Tressa E Pappas; Rose F Vrtis; Elizabeth A Kelly; James E Gern; Nizar N Jarjour Journal: Am J Respir Crit Care Med Date: 2011-11-01 Impact factor: 21.405
Authors: Jerry A Krishnan; Robert F Lemanske; Glorisa J Canino; Kurtis S Elward; Meyer Kattan; Elizabeth C Matsui; Herman Mitchell; E Rand Sutherland; Michael Minnicozzi Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Jeremy J Wildfire; Peter J Gergen; Christine A Sorkness; Herman E Mitchell; Agustin Calatroni; Meyer Kattan; Stanley J Szefler; Stephen J Teach; Gordon R Bloomberg; Robert A Wood; Andrew H Liu; Jacqueline A Pongracic; James F Chmiel; Kathleen Conroy; Yadira Rivera-Sanchez; William W Busse; Wayne J Morgan Journal: J Allergy Clin Immunol Date: 2012-01-12 Impact factor: 10.793
Authors: Stanley J Szefler; James F Chmiel; Anne M Fitzpatrick; George Giacoia; Thomas P Green; Daniel J Jackson; Heber C Nielsen; Wanda Phipatanakul; Hengameh H Raissy Journal: J Allergy Clin Immunol Date: 2013-11-28 Impact factor: 10.793